読み込み中
NASDAQHealthcareDrug Manufacturers - General
最新データ
$0.7455
+$0.0425 · +6.05%
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
前日終値
$0.7455
+$0.0425 · +6.05%
日中の時刻はETです。市場データは遅延する場合があります。
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
日中レンジ
現在 $0.7455
52週レンジ
現在 $0.7455
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
29
割高
センチメント
56
まちまち
リスク
76
高リスク
モメンタム
29
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
日中レンジ
現在 $0.7455
52週レンジ
現在 $0.7455
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 171.98万 USD | 330.56万 USD | 157.3万 USD | 235.15万 USD | 68.44万 USD |
| 販売・一般管理 | 877.33万 USD | 471.28万 USD | 649.95万 USD | 299.21万 USD | 77.01万 USD |
| 営業費用 | 1049.31万 USD | 801.83万 USD | 852.6万 USD | 704.79万 USD | 215.22万 USD |
| 受取利息 | 9.89万 USD | — | — | — | — |
| 支払利息 | — | 16.57万 USD | 345.63万 USD | 1.03万 USD | 2.44万 USD |
| 減価償却費と償却費 | — | — | — | 704.79万 USD | 215.22万 USD |
| 営業利益 | −1049.31万 USD | −801.83万 USD | −852.6万 USD | −704.79万 USD | −215.22万 USD |
| 純利益 | −1044.25万 USD | −785.27万 USD | −1198.23万 USD | −705.82万 USD | −217.65万 USD |
会社概要が更新されました 2026年10月12日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
